Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study - PubMed (original) (raw)
Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study
Murray B Resnick et al. Mod Pathol. 2005 Apr.
Free article
Abstract
Tight junction associated proteins are key molecular components governing cellular adhesion, polarity and glandular differentiation. Tight junction proteins also play critical roles in cellular proliferation and neoplastic pathways via their functions as couplers of the extracellular milieu to intracellular signaling pathways and the cytoskeleton. Neoplastic cells frequently exhibit structural and functional deficiencies in the tight junction. The purpose of this study was to determine the pattern of expression and prognostic value of four tight junction associated proteins, claudin-1, claudin-4, occludin and ZO-1 in a cohort of TNM stage II colon cancer using tissue microarray technology. In this study, we retrospectively analyzed, resected and otherwise untreated paraffin embedded specimens from 129 consecutive patients with TNM stage II colonic carcinomas for claudin-1, claudin-4, occludin and ZO-1 protein expression by immunohistochemistry. Seventy-five, 58, 56 and 44% of the tumors exhibited normal to elevated expression levels (+2 and +3 immunopositivity) of claudin-1, claudin-4, occludin and ZO-1 respectively. Low expression levels of claudin-1 and ZO-1 were directly associated with higher tumor grade (P=0.05 and 0.03 respectively). Multivariate analysis indicated that lymphovascular invasion (P=0.01) and low levels of claudin-1 (P=0.0001) expression were independent predictors of recurrence and that reduced claudin-1 expression (P=0.0001) was associated with poor survival. This study is the first to comprehensively examine the expression of several tight junction associated proteins in colonic neoplasms and to correlate their expression with disease progression. Loss of claudin-1 expression proved to be a strong predictor of disease recurrence and poor patient survival in stage II colon cancer.
Similar articles
- Claudin-1 and claudin-5 expression patterns differentiate lung squamous cell carcinomas from adenocarcinomas.
Paschoud S, Bongiovanni M, Pache JC, Citi S. Paschoud S, et al. Mod Pathol. 2007 Sep;20(9):947-54. doi: 10.1038/modpathol.3800835. Epub 2007 Jun 22. Mod Pathol. 2007. PMID: 17585317 - Expression of tight-junction-associated proteins in human gastric cancer: downregulation of claudin-4 correlates with tumor aggressiveness and survival.
Ohtani S, Terashima M, Satoh J, Soeta N, Saze Z, Kashimura S, Ohsuka F, Hoshino Y, Kogure M, Gotoh M. Ohtani S, et al. Gastric Cancer. 2009;12(1):43-51. doi: 10.1007/s10120-008-0497-0. Epub 2009 Apr 24. Gastric Cancer. 2009. PMID: 19390931 - The roles of claudin superfamily proteins in paracellular transport.
Heiskala M, Peterson PA, Yang Y. Heiskala M, et al. Traffic. 2001 Feb;2(2):93-8. doi: 10.1034/j.1600-0854.2001.020203.x. Traffic. 2001. PMID: 11247307 Review. - MicroRNA Regulation of Endothelial Junction Proteins and Clinical Consequence.
Zhuang Y, Peng H, Mastej V, Chen W. Zhuang Y, et al. Mediators Inflamm. 2016;2016:5078627. doi: 10.1155/2016/5078627. Epub 2016 Nov 24. Mediators Inflamm. 2016. PMID: 27999452 Free PMC article. Review.
Cited by
- Micro RNA-175 Targets Claudin-1 to Inhibit Madin-Darby Canine Kidney Cell Adhesion.
Li X, Ma F, Wang S, Tang T, Ma L, Qiao Z, Ma Z, Wang J, Liu Z. Li X, et al. Genes (Basel). 2024 Oct 16;15(10):1333. doi: 10.3390/genes15101333. Genes (Basel). 2024. PMID: 39457456 Free PMC article. - High Expression of CLDN 18.2 is Associated with Poor Disease-Free Survival of HER-2 Positive Gastric Cancer.
Zhang T, He Z, Liu Y, Jin L, Wang T. Zhang T, et al. Int J Gen Med. 2024 Apr 29;17:1695-1705. doi: 10.2147/IJGM.S453883. eCollection 2024. Int J Gen Med. 2024. PMID: 38706745 Free PMC article. - The Expression of the Claudin Family of Proteins in Colorectal Cancer.
Cox KE, Liu S, Hoffman RM, Batra SK, Dhawan P, Bouvet M. Cox KE, et al. Biomolecules. 2024 Feb 24;14(3):272. doi: 10.3390/biom14030272. Biomolecules. 2024. PMID: 38540693 Free PMC article. Review. - Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer.
Xu Q, Jia C, Ou Y, Zeng C, Jia Y. Xu Q, et al. Front Oncol. 2024 Mar 6;14:1371421. doi: 10.3389/fonc.2024.1371421. eCollection 2024. Front Oncol. 2024. PMID: 38511141 Free PMC article. Review. - Claudin 18.2 as a novel therapeutic target.
Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K. Nakayama I, et al. Nat Rev Clin Oncol. 2024 May;21(5):354-369. doi: 10.1038/s41571-024-00874-2. Epub 2024 Mar 19. Nat Rev Clin Oncol. 2024. PMID: 38503878 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous